

Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

- 3 | **Secrets of Drug Resistance in NSCLC Exposed by New Molecular Definition of EMT**
Dana S. Neel and Trever G. Bivona
See article, p. 279

CCR Perspectives in Drug Approval

- 6 | **Technology Assessment for New Oncology Drugs**
Bengt Jönsson

Statistics in Clinical Cancer Research

- 12 | **Competing Risks and Multistate Models**
Claudia Schmoor, Martin Schumacher, Jürgen Finke, and Jan Beyersmann

CCR Drug Updates

- 22 | **Brentuximab Vedotin**
Changchun Deng, Beiqing Pan, and Owen A. O'Connor

Molecular Pathways

- 28 | **Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer**
Fabrice Andre, Maria V. Dieci, Peter Dubsy, Christos Sotiriou, Giuseppe Curigliano, Carsten Denkert, and Sherene Loi
- 34 | **Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy**
Qin Li and Guillermina Lozano

HUMAN CANCER BIOLOGY

- 42 | **Impact of Ischemia and Procurement Conditions on Gene Expression in Renal Cell Carcinoma**
Nick W. Liu, Thomas Sanford, Ramaprasad Srinivasan, Jack L. Liu, Kiranpreet Khurana, Olga Aprelikova, Vladimir Valero, Charles Bechert, Robert Worrell, Peter A. Pinto, Youfeng Yang, Maria Merino, W. Marston Linehan, and Gennady Bratslavsky
- 50 | **The Severity of Neural Invasion Is Associated with Shortened Survival in Colon Cancer**
Florian Liebl, Ihsan Ekin Demir, Robert Rosenberg, Alexandra Boldis, Esra Yildiz, Kristina Kujundzic, Timo Kehl, Dominic Dischl, Tibor Schuster, Matthias Maak, Karen Becker, Rupert Langer, Melanie Laschinger, Helmut Friess, and Güralp O. Ceyhan
- 62 | **The Critical Role of Dysregulated FOXM1–PLAUR Signaling in Human Colon Cancer Progression and Metastasis**
Dawei Li, Ping Wei, Zhihai Peng, Chen Huang, Huamei Tang, Zhiliang Jia, Jiujie Cui, Xiangdong Le, Suyun Huang, and Keping Xie
- 73 | **miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways**
Shahana Majid, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari, Sumit Arora, Mohd Saif Zaman, Inik Chang, Soichiro Yamamura, Yuichiro Tanaka, Takeshi Chiyomaru, Guoren Deng, and Rajvir Dahiya

CANCER THERAPY: PRECLINICAL

- 85 | **Combined Administration of Rituximab and ON 013105 Induces Apoptosis in Mantle Cell Lymphoma Cells and Reduces Tumor Burden in a Mouse Model of Mantle Cell Lymphoma**
Anil Prasad, Ashutosh Shrivastava, Evangelos Papadopoulos, Paula M. Kuzontkoski, M.V. Ramana Reddy, Amanda M. Gillum, Ramesh Kumar, E. Premkumar Reddy, and Jerome E. Groopman

- 96 **Targeting the Phosphoinositide 3-Kinase p110- α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer**
Anna Wojtalla, Barbara Fischer, Nataliya Kotelevets, Francesco A. Mauri, Jens Sobek, Hubert Rehrauer, Carlos Wotzkow, Mario P. Tschan, Michael J. Seckl, Uwe Zangemeister-Wittke, and Alexandre Arcaro
- 106 **Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma**
Serena K. Perna, Biagio De Angelis, Daria Pagliara, Sayyeda T. Hasan, Lan Zhang, Aruna Mahendravada, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Gianpietro Dotti, and Barbara Savoldo
- 118 **Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer**
Junyao Xu, Jennifer J. Knox, Emin Ibrahimov, Eric Chen, Stefano Serra, Ming Tsao, Pinjiang Cao, Douglass Vines, David E. Green, Cristiane Metran-Nascente, Mairead G. McNamara, and David W. Hedley
- 128 **Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells**
Si Wang, Roberta Noberini, John L. Stebbins, Swadesh Das, Ziming Zhang, Bainan Wu, Sayantan Mitra, Sandrine Bilet, Ana Fernandez, Neil A. Bhowmick, Shinichi Kitada, Elena B. Pasquale, Paul B. Fisher, and Maurizio Pellicchia
- 138 **Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models**
Roberta Rosa, Roberta Marciano, Umberto Malapelle, Luigi Formisano, Lucia Nappi, Claudia D'Amato, Valentina D'Amato, Vincenzo Damiano, Gabriella Marfè, Silvana Del Vecchio, Antonella Zannetti, Adelaide Greco, Alfonso De Stefano, Chiara Carlomagno, Bianca Maria Veneziani, Giancarlo Troncone, Sabino De Placido, and Roberto Bianco
- 148 **Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB₃₈₉EGF for the Treatment of Bladder Cancer**
Xiaoping Yang, Elizabeth Kessler, Lih-Jen Su, Andrew Thorburn, Arthur E. Frankel, Yuan Li, Francisco G. La Rosa, Jingping Shen, Chuan-Yuan Li, Marileila Varela-Garcia, L. Michael Glodé, and Thomas W. Flaig
- 158 **Molecular Imaging Reveals a Role for AKT in Resistance to Cisplatin for Ovarian Endometrioid Adenocarcinoma**
Hanxiao Wang, Stefanie Galbán, Rong Wu, Brittany M. Bowman, Amanda Witte, Katrin Vetter, Craig J. Galbán, Brian D. Ross, Kathleen R. Cho, and Alnawaz Rehemtulla
- 170 **Endoglin (CD105) Contributes to Platinum Resistance and Is a Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer**
Angela J. Ziebarth, Somaira Newsheen, Adam D. Steg, Monjri M. Shah, Ashwini A. Katre, Zachary C. Dobbin, Hee-Dong Han, Gabriel Lopez-Berestein, Anil K. Sood, Michael Conner, Eddy S. Yang, and Charles N. Landen
- IMAGING, DIAGNOSIS, PROGNOSIS**
- 183 **Development of [¹¹C]erlotinib Positron Emission Tomography for *In Vivo* Evaluation of EGF Receptor Mutational Status**
Idris Bahce, Egbert F. Smit, Mark Lubberink, Astrid A. M. van der Veldt, Maqsood Yaqub, Albert D. Windhorst, Robert C. Schuit, Erik Thunnissen, Daniëlle A. M. Heideman, Pieter E. Postmus, Adriaan A. Lammertsma, and N. Harry Hendrikse
- 194 **Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation**
Johan Botling, Karolina Edlund, Miriam Lohr, Birte Hellwig, Lars Holmberg, Mats Lambe, Anders Berglund, Simon Ekman, Michael Bergqvist, Fredrik Pontén, André König, Oswaldo Fernandes, Mats Karlsson, Gisela Helenius, Christina Karlsson, Jörg Rahnenführer, Jan G. Hengstler, and Patrick Micke
- CANCER THERAPY: CLINICAL**
- 205 **Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein**
Courtney A. Crane, Seunggu J. Han, Brian Ahn, Jessica Oehlke, Valerie Kivett, Anne Fedoroff, Nicholas Butowski, Susan M. Chang, Jennifer Clarke, Mitchel S. Berger, Michael W. McDermott, Michael D. Prados, and Andrew T. Parsa

215 **Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone**

Charles J. Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Gwenaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S. Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, and Winald R. Gerritsen

225 **Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials**

Clemens Giessen, Ruediger Paul Laubender, Donna Pauler Ankerst, Sebastian Stintzing, Dominik Paul Modest, Ulrich Mansmann, and Volker Heinemann

236 **Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors**

Fariba Navid, Sharyn D. Baker, M. Beth McCarville, Clinton F. Stewart, Catherine A. Billups, Jianrong Wu, Andrew M. Davidoff, Sheri L. Spunt, Wayne L. Furman, Lisa M. McGregor, Shuiying Hu, John C. Panetta, David Turner, Demba Fofana, Wilburn E. Reddick, Wing Leung, and Victor M. Santana

247 **A Novel HLA-A*0201 Restricted Peptide Derived from Cathepsin G Is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia**

Mao Zhang, Pariya Sukhumalchandra, Atim A. Enyenihi, Lisa S. St. John, Sally A. Hunsucker, Elizabeth A. Mittendorf, Anna Sergeeva, Kathryn Ruisaard, Zein Al-Atrache, Patricia A. Ropp, Haroon Jakher, Tania Rodriguez-Cruz, Gregory Lizee, Karen Clise-Dwyer, Sijie Lu, Jeffrey J. Mollrem, Gary L. Glish, Paul M. Armistead, and Gheath Alatrash

258 **A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer**

Jordan Berlin, Johanna C. Bendell, Lowell L. Hart, Irfan Firdaus, Ira Gore, Robert C. Hermann, Mary F. Mulcahy, Mark M. Zalupski, Howard M. Mackey, Robert L. Yauch, Richard A. Graham, Gordon L. Bray, and Jennifer A. Low

268 **A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinecan Pegol in Patients with Refractory Solid Tumors**

Gayle S. Jameson, John T. Hamm, Glen J. Weiss, Carlos Alemany, Stephen Anthony, Michele Basche, Ramesh K. Ramanathan, Mitesh J. Borad, Raoul Tibes, Allen Cohn, Ioana Hinshaw, Robert Jotte, Lee S. Rosen, Ute Hoch, Michael A. Eldon, Robert Medve, Katrina Schroeder, Erica White, and Daniel D. Von Hoff

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

279 **An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance**

Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, Youhong Fan, Uma Giri, Praveen K. Tumula, Monique B. Nilsson, Jayanthi Gudikote, Hai Tran, Robert J.G. Cardnell, David J. Bearss, Steven L. Warner, Jason M. Foulks, Steven B. Kanner, Varsha Gandhi, Nancy Krett, Steven T. Rosen, Edward S. Kim, Roy S. Herbst, George R. Blumenschein, J. Jack Lee, Scott M. Lippman, K. Kian Ang, Gordon B. Mills, Waun K. Hong, John N. Weinstein, Ignacio I. Wistuba, Kevin R. Coombes, John D. Minna, and John V. Heymach

See commentary, p. 3

291 **Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models**

Jennifer R. Diamond, S. Gail Eckhardt, Aik Choon Tan, Timothy P. Newton, Heather M. Selby, Kelsey L. Brunkow, Maria I. Kachaeva, Marileila Varela-Garcia, Todd M. Pitts, Mark R. Bray, Graham C. Fletcher, and John J. Tentler

LETTERS TO THE EDITOR

304 **IGKC and Prognosis in Breast Cancer—Letter**

Marcus Schmidt, Patrick Micke, and Jan G. Hengstler

305 **IGKC and Prognosis in Breast Cancer—Response**

Theresa L. Whiteside and Soldano Ferrone

CORRECTION

306


Correction: The Impact of Non-Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials**RETRACTION**

307

Retraction: DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies

ABOUT THE COVER

Photomicrograph of MDA-MB-134-VI triple-negative breast cancer (TNBC) cells stained for senescence-associated β -galactosidase activity. Diamond and colleagues investigated the efficacy of the Aurora and angiogenic kinase inhibitor ENMD-2076 against preclinical models of breast cancer and showed robust activity in TNBC models, an area of unmet need. MDA-MB-134-VI cells showed inherent resistance to ENMD-2076, which was associated with markers of cellular senescence such as increased β -galactosidase activity and cell size. These investigators further showed that TNBC cell lines with mutant p53 and increased p53 protein expression were more sensitive to the proapoptotic effects of ENMD-2076 than mutant p53 cell lines that showed decreased p53 expression. These phenotypic differences could serve as predictive biomarkers of response to ENMD-2076 and other Aurora kinase inhibitors, which may prove useful in selecting TNBC patients for future clinical trials. For details, see the article by Diamond and colleagues on page 291 of this issue.



Clinical Cancer Research

19 (1)

Clin Cancer Res 2013;19:1-307.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/19/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.